PMID- 34988550
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 2688-6146 (Electronic)
IS  - 2688-6146 (Linking)
VI  - 3
IP  - Suppl 1
DP  - 2022 Jan
TI  - New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.
PG  - 11-23
LID - 10.1002/jha2.323 [doi]
AB  - CD19 directed chimeric antigen receptor T-cell therapy (CAR-T) represents a 
      significant advancement for patients with relapsed/refractory large B-cell 
      lymphoma (LBCL). Long term follow-up confirms durable remissions in nearly half 
      of the patients, a population which was previously estimated to have a median 
      survival of around 6 months with standard salvage therapy. This initial success 
      of CAR-T has led to significant expansion across other lymphoma histologies 
      resulting in the recent regulatory approval of CAR-T in mantle cell lymphoma and 
      follicular lymphoma. Additionally, multiple novel platforms of CAR-T therapy are 
      under development to improve efficacy and limit toxicity such dual antigen 
      targeting, allogeneic and natural killer CAR's. In this review, we focus on the 
      new indications of CAR-T in lymphomas beyond LBCL as well as emerging platforms 
      of CAR-T therapy.
FAU - Iqbal, Madiha
AU  - Iqbal M
AD  - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
FAU - Savani, Bipin N
AU  - Savani BN
AD  - Division of Hematology and Oncology, Vanderbilt University, Nashville, TN.
FAU - Hamadani, Mehdi
AU  - Hamadani M
AD  - Blood & Marrow Transplantation and Cellular Therapy Program, Division of 
      Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.
LA  - eng
GR  - U24 CA076518/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20211123
PL  - United States
TA  - EJHaem
JT  - EJHaem
JID - 101761942
PMC - PMC8725814
MID - NIHMS1766252
OTO - NOTNLM
OT  - CAR-T
OT  - allogeneic CAR
OT  - dual CAR
OT  - follicular lymphoma
OT  - lymphoma
OT  - mantle cell
COIS- Mehdi Hamadani reports Research Support/Funding: Takeda Pharmaceutical Company; 
      Otsuka Pharmaceutical; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: 
      Medimmune LLC; Janssen R & D; Incyte Corporation; ADC Therapeutics; Cellerant 
      Therapeutics; Celgene Corporation; Pharmacyclics, Magenta Therapeutics, Omeros, 
      AbGenomics, Verastem, TeneoBio. Speaker's Bureau: Sanofi Genzyme, AstraZeneca.
EDAT- 2022/01/07 06:00
MHDA- 2022/01/07 06:01
PMCR- 2021/11/23
CRDT- 2022/01/06 06:06
PHST- 2022/01/06 06:06 [entrez]
PHST- 2022/01/07 06:00 [pubmed]
PHST- 2022/01/07 06:01 [medline]
PHST- 2021/11/23 00:00 [pmc-release]
AID - JHA2323 [pii]
AID - 10.1002/jha2.323 [doi]
PST - ppublish
SO  - EJHaem. 2022 Jan;3(Suppl 1):11-23. doi: 10.1002/jha2.323. Epub 2021 Nov 23.